Overview: Glioma Prognostic Panel TestIntroduction: The Glioma Prognostic Panel Test analyzes genetic markers to predict glioma outcomes, aiding treatment for brain tumors causing headaches or seizures. Aligned with 2023 ASCO guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding personalized treatment and improving outcomes in molecular pathology for patients with suspected gliomas. It helps determine prognosis and tailor therapies like chemotherapy or radiation.
Other Names: Glioma Panel Assay, Brain Tumor Prognostic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Glioma genetic testing began in the 2000s with brain tumor research. PCR-based panels emerged in the 2010s, improving prognostic accuracy for gliomas.
Purpose: Predicts glioma outcomes, guides treatment, and monitors genetic markers in patients with headaches, seizures, or neurological symptoms.
Test Parameters: 1. Glioma Prognostic Markers
Pretest Condition: No fasting required. Collect tissue or whole blood at any time. Report symptoms like headaches, seizures, or neurological deficits, and list treatment history.
Specimen: 0.5-2 cma³ tissue (sterile container) or 2-5 mL whole blood (EDTA). Transport in a biohazard bag within 24 hours to maintain DNA integrity.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document headaches, seizures, or history of brain tumors. Include current medications, especially chemotherapeutics or anticonvulsants, and prior treatments.
Consent: Written consent required, detailing the tests purpose, prognostic implications, and potential need for targeted therapy or clinical trials.
Procedural Considerations: Uses PCR to analyze glioma prognostic markers (e.g., IDH1, MGMT mutations). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often integrated with tumor profiling.
Factors Affecting Result Accuracy: Low DNA yield, poor sample quality, or tumor heterogeneity can affect results. Contamination may lead to false results.
Clinical Significance: Identified markers (e.g., IDH1 mutation) guide treatment (e.g., temozolomide) and predict outcomes. Negative results may require alternative testing or clinical correlation.
Specialist Consultation: Consult a neuro-oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, tumor biopsy, or liquid biopsy to confirm glioma diagnosis and refine prognosis.
Test Limitations: Tumor heterogeneity may miss critical markers. Variants of unknown significance require clinical correlation.
References: ASCO Glioma Guidelines, 2023; Neuro-Oncology, Louis DN, 2022.
